328 related articles for article (PubMed ID: 2986648)
1. Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet.
Terashita Z; Imura Y; Nishikawa K
Biochem Pharmacol; 1985 May; 34(9):1491-5. PubMed ID: 2986648
[TBL] [Abstract][Full Text] [Related]
2. PAF binding sites. Characterization by [3H]52770 RP, a pyrrolo[1,2-c]thiazole derivative, in rabbit platelets.
Robaut C; Durand G; James C; Lave D; Sedivy P; Floch A; Mondot S; Pacot D; Cavero I; Le Fur G
Biochem Pharmacol; 1987 Oct; 36(19):3221-9. PubMed ID: 2822048
[TBL] [Abstract][Full Text] [Related]
3. Binding of [3H]SR 27417, a novel platelet-activating factor (PAF) receptor antagonist, to rabbit and human platelets and polymorphonuclear leukocytes.
Herbert JM; Laplace MC; Maffrand JP
Biochem Pharmacol; 1993 Jan; 45(1):51-8. PubMed ID: 8381007
[TBL] [Abstract][Full Text] [Related]
4. Species difference in the specific receptors of platelet activating factor.
Hwang SB; Lam MH
Biochem Pharmacol; 1986 Dec; 35(24):4511-8. PubMed ID: 3024653
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of platelet activating factor receptor binding and stimulated phosphoinositide-specific phospholipase C in rabbit platelets.
Morrison WJ; Shukla SD
J Pharmacol Exp Ther; 1989 Sep; 250(3):831-5. PubMed ID: 2550620
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
7. Effect of SR 27417 on the binding of [3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes.
Herbert JM; Laplace MC; Cailleau C; Maffrand JP
J Lipid Mediat; 1993 May; 7(1):57-78. PubMed ID: 8395255
[TBL] [Abstract][Full Text] [Related]
8. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
[TBL] [Abstract][Full Text] [Related]
11. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets.
Tahraoui L; Floch A; Cavero I
J Pharmacol Exp Ther; 1990 Mar; 252(3):1221-7. PubMed ID: 2156995
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic characterization of the rabbit neutrophil receptor for platelet-activating factor.
Paulson SK; Wolf JL; Novotney-Barry A; Cox CP
Proc Soc Exp Biol Med; 1990 Nov; 195(2):247-54. PubMed ID: 2172997
[TBL] [Abstract][Full Text] [Related]
13. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
[TBL] [Abstract][Full Text] [Related]
14. Characterization of specific binding sites of 3H-labelled platelet-activating factor ([3H]PAF) and a new antagonist, [3H]SR 27417, on guinea-pig tracheal epithelial cells.
Herbert JM
Biochem J; 1992 May; 284 ( Pt 1)(Pt 1):201-6. PubMed ID: 1318021
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological evidence for the putative existence of two different subtypes of PAF receptors on platelets and leukocytes; studies with yangambin.
Herbert JM; Castro-Faria-Neto HC; Barbosa-Filho JM; Cordeiro RS; Tibiriça E
J Lipid Mediat Cell Signal; 1997 Sep; 17(1):1-14. PubMed ID: 9302650
[TBL] [Abstract][Full Text] [Related]
16. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988.
Nunez D; Chignard M; Korth R; Le Couedic JP; Norel X; Spinnewyn B; Braquet P; Benveniste J
Eur J Pharmacol; 1986 Apr; 123(2):197-205. PubMed ID: 3086108
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
Herbert JM; Laplace MC; Maffrand JP
J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
[TBL] [Abstract][Full Text] [Related]
18. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
19. Identification of a second putative receptor of platelet-activating factor from human polymorphonuclear leukocytes.
Hwang SB
J Biol Chem; 1988 Mar; 263(7):3225-33. PubMed ID: 2830276
[TBL] [Abstract][Full Text] [Related]
20. trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor.
Hwang SB; Lam MH; Biftu T; Beattie TR; Shen TY
J Biol Chem; 1985 Dec; 260(29):15639-45. PubMed ID: 2999126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
